Drug Trial Radar · NCT06906471
A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Actual
Start
Jul 1, 2026
Primary completion
Oct 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Antelope Surgical Solutions, IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Single-Arm, blinded, fluorescent PSMA histopathology trial of AS1986NS
Conditions
- Prostate Cancer
- Prostate Cancer (Adenocarcinoma)
- Fluorescence Imaging
Interventions
AS1986NSDrug
Single dose, IV, 100 µg of AS1986NS
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of AS1986NSTime frame: Enrollment to 30 days post single infusion
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
HCA Florida Kendall Hospital
Miami, Florida
Icahn School of Medicine at Mount Sinai (ISMMS)
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.